izpis_h1_title_alt

Discovery of novel Hsp90 C-terminal inhibitors using 3D-pharmacophores derived from molecular dynamics simulations
ID Tomašič, Tihomir (Author), ID Durcik, Martina (Author), ID Keegan, Bradley M. (Author), ID Gramec, Darja (Author), ID Zajec, Živa (Author), ID Blagg, Brian S. J. (Author), ID Bryant, Sharon D. (Author)

.pdfPDF - Presentation file, Download (7,84 MB)
MD5: 1AFE40E52733E2787B755148491CF7D1
URLURL - Source URL, Visit https://www.mdpi.com/1422-0067/21/18/6898 This link opens in a new window

Abstract
Hsp90 C-terminal domain (CTD) inhibitors are promising novel agents for cancer treatment, as they do not induce the heat shock response associated with Hsp90 N-terminal inhibitors. One challenge associated with CTD inhibitors is the lack of a co-crystallized complex, requiring the use of predicted allosteric apo pocket, limiting structure-based (SB) design approaches. To address this, a unique approach that enables the derivation and analysis of interactions between ligands and proteins from molecular dynamics (MD) trajectories was used to derive pharmacophore models for virtual screening (VS) and identify suitable binding sites for SB design. Furthermore, ligand-based (LB) pharmacophores were developed using a set of CTD inhibitors to compare VS performance with the MD derived models. Virtual hits identified by VS with both SB and LB models were tested for antiproliferative activity. Compounds 9 and 11 displayed antiproliferative activities in MCF-7 and Hep G2 cancer cell lines. Compound 11 inhibited Hsp90-dependent refolding of denatured luciferase and induced the degradation of Hsp90 clients without the concomitant induction of Hsp70 levels. Furthermore, compound 11 offers a unique scaffold that is promising for the further synthetic optimization and development of molecules needed for the evaluation of the Hsp90 CTD as a target for the development of anticancer drugs.

Language:English
Keywords:allosteric, cancer, Hsp90, inhibitor, molecular dynamics, pharmacophores, virtual screening
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:22 str.
Numbering:Vol. 21, iss. 18, art. 6898
PID:20.500.12556/RUL-134472 This link opens in a new window
UDC:615.2:616-006-085
ISSN on article:1422-0067
DOI:10.3390/ijms21186898 This link opens in a new window
COBISS.SI-ID:29153795 This link opens in a new window
Publication date in RUL:17.01.2022
Views:1047
Downloads:192
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:International journal of molecular sciences
Shortened title:Int. j. mol. sci.
Publisher:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:20.09.2020

Secondary language

Language:Slovenian
Keywords:zaviralci, molekularna dinamika, zdravljenje raka, virtualno rešetanje, farmakofori, rak

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:J1-1717
Name:Razvoj novih zaviralcev Hsp90 s protitumornim delovanjem

Funder:ARRS - Slovenian Research Agency
Project number:BI-US/18-19078

Funder:Other - Other funder or multiple funders
Funding programme:COST
Project number:CA15135

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back